<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="114244"><DrugName>minocycline + edetate + ethyl alcohol (antibiotic lock solution, catheter-related bloodstream infections), Citius</DrugName><DrugNamesKey><Name id="43139984">Mino-Lok</Name></DrugNamesKey><DrugSynonyms><Name><Value>Mino-Lok</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>minocycline + edetate + ethyl alcohol (antibiotic lock solution, catheter-related bloodstream infections), MD Anderson Cancer Center</Value></Name><Name><Value>minocycline + edetate + ethyl alcohol (antibiotic lock solution, catheter-related bloodstream infections), Leonard-Meron Biosciences</Value></Name><Name><Value>minocycline + edetate + ethyl alcohol (antibiotic lock solution, catheter-related bloodstream infections), Citius</Value></Name></DrugSynonyms><CompanyOriginator id="23382">MD Anderson Cancer Center</CompanyOriginator><CompaniesPrimary><Company id="1077492">Citius Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1114952">Leonard Meron Biosciences Inc</Company><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1077492" type="Company"><TargetEntity id="5001218237" type="organizationId">Citius Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1114952" type="Company"><TargetEntity id="5043952156" type="organizationId">Leonard-Meron Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity></SourceEntity><SourceEntity id="33500" type="Action"><TargetEntity id="2716" type="Mechanism">30S Ribosomal Protein Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="40">Bacterial infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="33500">30S ribosomal protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1539">Tetracycline</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="175">Drug combination</Technology><Technology id="66">Antibiotic</Technology><Technology id="764">Local formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-30T09:39:42.000Z</LastModificationDate><ChangeDateLast>2019-05-02T00:00:00.000Z</ChangeDateLast><AddedDate>2019-01-14T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1077492" linkType="Company"&gt;Citius Pharmaceuticals&lt;/ulink&gt; (following its acquisition of &lt;ulink linkID="1114952" linkType="Company"&gt;Leonard-Meron Bioscience&lt;/ulink&gt; (LMB)), under license from &lt;ulink linkID="23382" linkType="Company"&gt;MD Anderson Cancer Center&lt;/ulink&gt; (MDACC), is developing Mino-Lok, an antibiotic lock solution containing a proprietary combination of &lt;ulink linkID="46889" linkType="Drug"&gt;minocycline&lt;/ulink&gt;, edetate (disodium EDTA) and ethyl alcohol, for the potential adjunctive treatment of catheter-related bloodstream infections (CRBSIs) [&lt;ulink linkID="1748312" linkType="Reference"&gt;1748312&lt;/ulink&gt;], [&lt;ulink linkID="1910973" linkType="Reference"&gt;1910973&lt;/ulink&gt;], [&lt;ulink linkID="2109183" linkType="Reference"&gt;2109183&lt;/ulink&gt;],  [&lt;ulink linkID="2109903" linkType="Reference"&gt;2109903&lt;/ulink&gt;]. In February 2018, a pivotal phase III trial assessing Mino-Lok in  combination with systemic antibiotics began. In July 2018, the trial was expected to complete in September 2019 [&lt;ulink linkID="2109913" linkType="Reference"&gt;2109913&lt;/ulink&gt;], [&lt;ulink linkID="2005473" linkType="Reference"&gt;2005473&lt;/ulink&gt;]; in December 2018, the trial was ongoing with interim analyses planned   [&lt;ulink linkID="2105530" linkType="Reference"&gt;2105530&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In October 2017, the FDA granted Fast Track designation to Mino-Lok [&lt;ulink linkID="1976277" linkType="Reference"&gt;1976277&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In October 2015, the FDA granted Qualified Infectious Disease Product to Mino-Lok for the treatment of catheter-related bloodstream infections [&lt;ulink linkID="1702435" linkType="Reference"&gt;1702435&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2019, data from meta-analysis of two separate studies conducted in four institutions in four different countries (MDA MLT ; Ex-U.S. MLT; All MLT  Treated and catheters salvaged), were reported. Data  showed that Mino-Lok was 98% effective   in salvaging catheters that caused bacteremia [&lt;ulink linkID="2146870" linkType="Reference"&gt;2146870&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2018, a  multi-center, randomized, open-label, assess-blind, phase III trial (&lt;ulink linkID="271522" linkType="Protocol"&gt;NCT02901717&lt;/ulink&gt;; MDA-2013-0039) began in the US and Puerto Rico to assess the efficacy and safety of Mino-Lok in combination with systemic standard-of-care antibiotics (iv) in patients (expected n = 700) with  catheter-related or central line-associated bloodstream infections. The primary endpoint was the proportion of subjects in the intent-to-treat population with overall success at the test of cure at 8 weeks.  In July 2018, the trial was expected to complete in September 2019 [&lt;ulink linkID="2109913" linkType="Reference"&gt;2109913&lt;/ulink&gt;], [&lt;ulink linkID="2005473" linkType="Reference"&gt;2005473&lt;/ulink&gt;]. In December 2018, it was noted that interim analyses at the 50% and 75% point of the trial were planned [&lt;ulink linkID="2105530" linkType="Reference"&gt;2105530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, a comparative, US, phase IIb trial was completed. The trial assessed Mino-Lok in patients (n = 90) with hematologic or solid tumor cancers receiving therapy through central venous catheters (CVC). Data demonstrated that the product salvaged the totality  of infected CVCs in the active arm (n = 30) with no serious adverse events, compared with an 18% serious adverse event rate in the matched cohort (n = 60)  where patients had the infected CVCs removed and replaced with a new CVC  [&lt;ulink linkID="2109903" linkType="Reference"&gt;2109903&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2018, Citius received notice from MDACC that the US Patent and Trademark Office has reviewed and examined a US patent protecting Mino-Lok and that it was allowed for issuance as a patent. In October 2018, the US patent was issued, which would extend protection until November 2036. Additionally, by December 2018,  European patents had also been granted covering the product throughout the year 2036 [&lt;ulink linkID="2056597" linkType="Reference"&gt;2056597&lt;/ulink&gt;], [&lt;ulink linkID="2105530" linkType="Reference"&gt;2105530&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1077492">Citius Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-13T00:00:00.000Z</StatusDate><Source id="2109913" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1077492">Citius Pharmaceuticals Inc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-13T00:00:00.000Z</StatusDate><Source id="2109913" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1077492">Citius Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-19T00:00:00.000Z</StatusDate><Source id="2105530" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1077492">Citius Pharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-23T00:00:00.000Z</StatusDate><Source id="1910973" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23382">MD Anderson Cancer Center</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-23T00:00:00.000Z</StatusDate><Source id="1910973" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23382">MD Anderson Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-31T00:00:00.000Z</StatusDate><Source id="2109903" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23382">MD Anderson Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-31T00:00:00.000Z</StatusDate><Source id="2109903" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23382">MD Anderson Cancer Center</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-31T00:00:00.000Z</StatusDate><Source id="2109903" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1114952">Leonard Meron Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-05-31T00:00:00.000Z</StatusDate><Source id="2109903" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1114952">Leonard Meron Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-31T00:00:00.000Z</StatusDate><Source id="2109903" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1077492">Citius Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Treatment of catheter-related bloodstream infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-31T00:00:00.000Z</MileStoneDate><Source id="1976277" type="PR"></Source></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="1114952">Leonard Meron Biosciences Inc</OwnerCompany><Country id="US">US</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Treatment of catheter-related bloodstream infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-31T00:00:00.000Z</MileStoneDate><Source id="1702435" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-06434"><Name>30S ribosomal protein</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1077492">Citius Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="252957" title="Citius Pharmaceuticals to develop MD Anderson Cancer Center's Mino-Lok for bacterial infection worldwide"></Deal></Deals><PatentFamilies><PatentFamily id="3625946" number="WO-2017079589" title="Antimicrobial solutions with enhanced stability"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Leonard Meron Biosciences Inc" id="1114952"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>